OncoOne

Don't forget: The 43rd Annual J.P. Morgan Healthcare Conference (#JPM2025) starts today. Meet our CEO, Randolf Kerschbaumer, and CSO, Michael Thiele on site in San Francisco to learn more about our oxMIF-targeting antibodies for cancer and inflammation, and the PreTarg-it® platform for targeted radiotherapy. Discover more about our pipeline here: https://lnkd.in/egaWCwMi   #OncoOne #Innovation #Investment #Collaboration #CancerResearch #JPM2025

Join us at #CHIPepTalk in San Diego, January 13-16, 2025! We’re excited to announce that our CSO, Michael Thiele, will be presenting at the #CHIPepTalk Congress on January 14 at 6 PM in the Targeted Radioligand Therapies stream. Don’t miss this opportunity to hear about our innovative radioimmunotherapy platform #PreTargit® , which leverages bispecific antibodies for enhanced tumor targeting and optimized delivery of radioactive payloads—addressing indications with high unmet medical need.   Mark your calendar and connect with Michael to learn more about how we’re pushing the boundaries of cancer therapy. See you there!   #OncoOne #Radioimmunotherapy #Pretargetedradioimmunotherapy #PRIT #Innovation #CHIPepTalk2024

OncoOne's Scientific Sprint: 5 Major Publications in One Year As 2024 comes to a close, OncoOne celebrates a sprint of success with 5 peer-reviewed publications, advancing our oxMIF-targeting antibodies for cancer and inflammation, alongside the development of our PreTarg-it® platform for targeted radiotherapy. Get the full text of our publications here: https://lnkd.in/e3Hh95FD A huge thank you to our exceptional team and partners for making this possible. We look forward to another successful year ahead! #OncoOne #TargetedTherapies #Publications #Immunotherapy #Cancertherapy #Cancer #Innovation #oxMIF #Biotech

We're delighted to announce OncoOne's latest publication in Antibodies MDPI!  In our latest publication, we explore how combining in silico tools with experimental validation can enhance antibody engineering. Focusing on the first-generation anti-oxMIF antibody, imalumab, we uncovered surface hydrophobicity and aggregation as key factors limiting its effectiveness. Through targeted mutations, we transformed these challenges into opportunities, developing C0083—a candidate with improved biophysicochemical properties, reduced immunogenicity risk, and enhanced pharmacokinetics. This advancement has laid the foundation for all of our anti-oxMIF assets targeting cancer and inflammation. Read more about our results here: https://lnkd.in/dtvNmsHw. Congratulations to first author Gregor Rossmüller for his outstanding contributions and many thanks Antibodies MDPI for the smooth editorial process! #AntibodyEngineering #AntibodyDevelopment #CancerTherapy #Inflammation #OncoOne #oxMIF #MDPIAntibodies #TargetedTherapies

As the year ends, we celebrate the diversity of traditions that make this season special. Whether you’re lighting candles, exchanging gifts, or finding time to reflect, we wish you joy, peace, and unity. From the OncoOne team, we wish you a joyful holiday season and a bright start to 2025!   #SeasonalGreetings #HappyHolidays #NewYear2025

Join OncoOne at #JPM2025 in San Francisco! From January 13-16, 2025, we’ll be at the J.P. Morgan Healthcare Conference, the premier event for biotech, pharma, and investors. Meet our CEO Randolf Kerschbaumer and CSO Michael Thiele in person to explore our oxMIF-targeting antibodies for cancer and inflammation, and the PreTarg-it® platform for targeted radiotherapy.   #OncoOne #Innovation #Investment #Collaboration #CancerResearch #JPM2025

🎗️ November is #PancreaticCancerAwarenessMonth! This month, and especially on #WorldPancreaticCancer Day, 21 November, we come together to raise awareness of one of the most challenging cancers. Despite advances in research, pancreatic cancer is still difficult to detect at an early stage, and survival rates are in urgent need of innovation and action. At OncoOne, we're committed to addressing cancers with high unmet medical need, including pancreatic cancer, through our innovative PreTarg-it® platform for pre-targeted radioimmunotherapy. Let’s wear purple, share stories, and advocate for progress against this devastating disease. Learn how you can make a difference: https://lnkd.in/dxAi_fz2: https://lnkd.in/dxAi_fz2   #PancreaticCancerAwareness #WorldPancreaticCancerDay #OncoOne #Innovation #CancerResearch

We’re excited for the Investival Showcase on November 18 in London! Connect with OncoOne’s CEO, Randolf Kerschbaumer, to learn about our oxMIF-targeting antibodies for inflammation and cancer, and the PreTarg-it® platform for targeted radiotherapy. Schedule a meeting via the conference platform: https://lnkd.in/eP7Cz4CS Let's explore partnering opportunities together! #InvestivalShowcase #OncoOne #oxMIF #PreTargit #Inflammation #Cancer #Radiotherapy #Biotech #LifeSciences #Partnerships

Have you secured your spot or planning to join us spontaneously? We are pleased to announce that Friedmund Bachmann, Vice President CMC, will be attending the European Association of Nuclear Medicine (EANM) 2024 conference in Hamburg! Join us to learn more about OncoOne’s latest advancements on our pretargeted radioimmunotherapy platform – PreTarg-it®.   Discover more about our PreTarg-it® platform here: https://lnkd.in/dcRSatNH   We look forward to seeing you there!   #EANM2024 #OncoOne #Oncology #radiopharmaceuticals #RIT #pretargeting #radioimmunotherapy #bispecificantibodies #antibodies

We are delighted to present our latest findings in PLOS ONE, which highlight the therapeutic potential of our anti-oxMIF antibody ON104 in kidney disease!   Our findings spotlight the exciting potential of targeting oxMIF in inflammatory kidney diseases. In a rat model of crescentic glomerulonephritis (CGN), the anti-oxMIF antibody ON104 significantly reduced disease severity—improving kidney function, preserving glomerular structure, and reducing inflammation. These encouraging results on the effectiveness of ON104 offer hope for new treatment options for glomerulonephritis and related conditions.   Huge congratulations to first author Maroua FERHAT from OncoOne and special thanks to Prof. Frederick W. K. Tam and his amazing team at Imperial College London for their invaluable collaboration.   Check out the full paper here: https://lnkd.in/dGU323em   #KidneyHealth #Inflammation #autoimmunediseases #Glomerulonephritis #nephritis #oxMIF #ON104 #OncoOne